|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tessen HW, Hutzschenreuter U, Steffens CC,
et al: The treatment of lung cancer in German outpatient centres.
Data from a clinical registry-TLK Registry. Onkologie. 34:153.
2011.
|
|
3
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Torimura T, Iwamoto H, Nakamura T, Koga H,
Ueno T, Kerbel RS and Sata M: Metronomic chemotherapy: Possible
clinical application in advanced hepatocellular carcinoma. Transl
Oncol. 6:511–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Benzekry S, Pasquier E, Barbolosi D,
Lacarelle B, Barlési F, André N and Ciccolini J: Metronomic
reloaded: Theoretical models bringing chemotherapy into the era of
precision medicine. Semin Cancer Biol. 35:53–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weiss JM and Stinchcombe TE: Second-line
therapy for advanced NSCLC. Oncologist. 18:947–953. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang S, Liu J and Cheng Y: Metronomic
chemotherapy-A new path to treat advanced non-small cell lung
cancer. Zhongguo Fei Ai Za Zhi. 18:232–239. 2015.(In Chinese).
PubMed/NCBI
|
|
8
|
Browder T, Butterfield CE, Kraling BM, Shi
B, Marshall B, O'Reilly MS and Folkman J: Antiangiogenic scheduling
of chemotherapy improves efficacy against experimental
drug-resistant cancer. Cancer Res. 60:1878–1886. 2000.PubMed/NCBI
|
|
9
|
Klement G, Baruchel S, Rak J, Man S, Clark
K, Hicklin DJ, Bohlen P and Kerbel RS: Continuous low-dose therapy
with vinblastine and VEGF receptor-2 antibody induces sustained
tumor regression without overt toxicity. J Clin Invest.
105:R15–R24. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Quoix E, Zalcman G, Oster JP, Westeel V,
Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L,
et al: Carboplatin and weekly paclitaxel doublet chemotherapy
compared with monotherapy in elderly patients with advanced
non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Lancet. 378:1079–1088. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Görn M, Habermann CR, Anige M, Thöm I,
Schuch G, Andritzky B, Brandl S, Burkholder I, Edler L, Hossfeld
DK, et al: A pilot study of docetaxel and trofosfamide as
second-line ‘metronomic’ chemotherapy in the treatment of
metastatic non-small cell lung cancer (NSCLC). Onkologie.
31:185–189. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Belani CP, Barstis J, Perry MC, La Rocca
RV, Nattam SR, Rinaldi D, Clark R and Mills GM: Multicenter,
randomized trial for stage IIIB or IV non-small-cell lung cancer
using weekly paclitaxel and carboplatin followed by maintenance
weekly paclitaxel or observation. J Clin Oncol. 21:2933–2939. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schuette W, Blankenburg T, Guschall W,
Dittrich I, Schroeder M, Schweisfurth H, Chemaissani A, Schumann C,
Dickgreber N, Appel T and Ukena D: Multicenter randomized trial for
stage IIIB/IV non-small-cell lung cancer using every-3-week versus
weekly paclitaxel/carboplatin. Clin Lung Cancer. 7:338–343. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Biganzoli L, Lichtman S, Michel JP,
Papamichael D, Quoix E, Walko C and Aapro M: Oral single-agent
chemotherapy in older patients with solid tumours: A position paper
from the International Society of Geriatric Oncology (SIOG). Eur J
Cancer. 51:2491–2500. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Camerini A, Banna GL, Cinieri S, Pezzuto
A, Mencoboni M, Rosetti F, Figueiredo A, Rizzo P, Ricci A,
Langenhoven L, et al: Metronomic oral vinorelbine for the treatment
of advanced non-small cell lung cancer: A multicenter international
retrospective analysis. Clin Transl Oncol. 21:790–795. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Camerini A, Valsuani C, Mazzoni F, Siclari
O, Puccetti C, Donati S, Rondini M, Tartarelli G, Puccinelli P, Di
Costanzo F and Amoroso D: Phase II trial of single-agent oral
vinorelbine in elderly (> or =70 years) patients with advanced
non-small-cell lung cancer and poor performance status. Ann Oncol.
21:1290–1295. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jassem J, Ramlau R, Karnicka-Mlodkowska H,
Krawczyk K, Krzakowski M, Zatloukal P, Lemarié E, Hartmann W,
Novakova L, O'Brien M and Depierr A: A multicenter randomized phase
II study of oral vs. intravenous vinorelbine in advanced
non-small-cell lung cancer patients. Ann Oncol. 12:1375–1381. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Camerini A, Puccetti C, Donati S, Valsuani
C, Petrella MC, Tartarelli G, Puccinelli P and Amoroso D:
Metronomic oral vinorelbine as first-line treatment in elderly
patients with advanced non-small cell lung cancer: Results of a
phase II trial (MOVE trial). BMC Cancer. 15:3592015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
D'Ascanio M, Pezzuto A, Fiorentino C,
Sposato B, Bruno P, Grieco A, Mancini R and Ricci A: Metronomic
chemotherapy with vinorelbine produces clinical benefit and low
toxicity in frail elderly patients affected by advanced non-small
cell lung cancer. Biomed Res Int. 2018:62784032018.PubMed/NCBI
|
|
20
|
Pujol JL, Coffy A, Camerini A, Kotsakis A,
Mencoboni M, Gusella M, Pasini F, Pezzuto A, Banna GL, Bilir C, et
al: An individual patient-data meta-analysis of metronomic oral
vinorelbine in metastatic non-small cell lung cancer. PLoS One.
14:e02209882019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pasini F, Barile C, Caruso D, Modena Y,
Fraccon AP, Bertolaso L, Menon D, La Russa F, Crepaldi G, Bononi A,
et al: Oral metronomic vinorelbine (OMV) in elderly or pretreated
patients with advanced non small cell lung cancer: Outcome and
pharmacokinetics in the real world. Invest New Drugs. 36:927–932.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huizing MT, Misser VH, Pieters RC, ten
Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM and Beijnen
JH: Taxanes: A new class of antitumor agents. Cancer Invest.
13:381–404. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gervais R, Ducolone A, Breton JL, Braun D,
Lebeau B, Vaylet F, Debieuvre D, Pujol JL, Tredaniel J, Clouet P
and Quoix E: Phase II randomised trial comparing docetaxel given
every 3 weeks with weekly schedule as second-line therapy in
patients with advanced non-small-cell lung cancer (NSCLC). Ann
Oncol. 16:90–96. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Camps C, Massuti B, Jimenez A, Maestu I,
Gómez RG, Isla D, González JL, Almenar D, Blasco A, Rosell R, et
al: Randomized phase III study of 3-weekly versus weekly docetaxel
in pretreated advanced non-small-cell lung cancer: A Spanish Lung
Cancer Group trial. Ann Oncol. 17:467–472. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Katsaounis P, Kotsakis A, Agelaki S,
Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou
A, Karachaliou N, Hatzidaki D and Georgoulias V: Cisplatin in
combination with metronomic vinorelbine as front-line treatment in
advanced non-small cell lung cancer: A multicenter phase II study
of the Hellenic Oncology Research Group (HORG). Cancer Chemother
Pharmacol. 75:821–827. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bozec A, Fischel JL and Milano G:
Epidermal growth factor receptor/angiogenesis dual targeting:
preclinical experience. Curr Opin Oncol. 18:330–334. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kontopodis E, Hatzidaki D, Varthalitis I,
Kentepozidis N, Giassas S, Pantazopoulos N, Vardakis N, Rovithi M,
Georgoulias V and Agelaki S: A phase II study of metronomic oral
vinorelbine administered in the second line and beyond in non-small
cell lung cancer (NSCLC): A phase II study of the Hellenic Oncology
Research Group. J Chemotherapy. 25:49–55. 2013. View Article : Google Scholar
|
|
28
|
Hainsworth JD, Burris HA III, Litchy S,
Morrissey LH, Barton JH, Bradof JE and Greco FA: Weekly docetaxel
in the treatment of elderly patients with advanced nonsmall cell
lung carcinoma. A Minnie Pearl Cancer Research Network Phase II
Trial. Cancer. 89:328–333. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Noronha V, Patil VM, Joshi A and Prabhash
K: Efficacy and safety of metronomic administration of paclitaxel
for advanced recurrent non-small-cell lung cancer. Indian J Cancer.
50:122–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kouroussis C, Vamvakas L, Vardakis N,
Kotsakis A, Kalykaki A, Kalbakis K, Saridaki Z, Kentepozidis N,
Giassas S and Georgoulias V: Continuous administration of daily
low-dose temozolomide in pretreated patients with advanced
non-small cell lung cancer: A phase II study. Oncology. 76:112–117.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dziadziuszko R, Ardizzoni A, Postmus PE,
Smit EF, Price A, Debruyne C, Legrand C and Giaccone G; EORTC Lung
Cancer Group, : Temozolomide in patients with advanced non-small
cell lung cancer with and without brain metastases: A phase II
study of the EORTC Lung Cancer Group (08965). Eur J Cancer.
39:1271–1276. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Correale P, Cerretani D, Remondo C,
Martellucci I, Marsili S, La Placa M, Sciandivasci A, Paolelli L,
Pascucci A, Rossi M, et al: A novel metronomic chemotherapy regimen
of weekly platinum and daily oral etoposide in high-risk non-small
cell lung cancer patients. Oncol Rep. 16:133–140. 2006.PubMed/NCBI
|
|
33
|
Hirsch FR, Suda K, Wiens J and Bunn PA Jr:
New and emerging targeted treatments in advanced non-small-cell
lung cancer. Lancet. 388:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Giaccone G, Herbst RS, Manegold C,
Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel
J, Pluzanska A, et al: Gefitinib in combination with gemcitabine
and cisplatin in advanced non-small-cell lung cancer: A phase III
trial-INTACT 1. J Clin Oncol. 22:777–784. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Herbst RS, Giaccone G, Schiller JH, Natale
RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves
JA, et al: Gefitinib in combination with paclitaxel and carboplatin
in advanced non-small-cell lung cancer: A phase III trial-INTACT 2.
J Clin Oncol. 22:785–794. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Herbst RS, Prager D, Hermann R,
Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P,
Li X, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride
(OSI-774) combined with carboplatin and paclitaxel chemotherapy in
advanced non-small-cell lung cancer. J Clin Oncol. 23:5892–5899.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gatzemeier U, Pluzanska A, Szczesna A,
Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H,
Pesek M, Serwatowski P, et al: Phase III study of erlotinib in
combination with cisplatin and gemcitabine in advanced
non-small-cell lung cancer: The Tarceva Lung Cancer Investigation
Trial. J Clin Oncol. 25:1545–1552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kerbel RS and Kamen BA: The
anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer.
4:423–436. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen YM, Fan WC, Tsai CM, Liu SH, Shih JF,
Chou TY, Wu CH, Chou KT, Lee YC, Perng RP, et al: A Phase II
randomized trial of gefitinib alone or with tegafur/uracil
treatment in patients with pulmonary adenocarcinoma who had failed
previous chemotherapy. J Thorac Oncol. 6:1110–1116. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sutiman N, Zhang ZX, Tan EH, Ang MK, Tan
SW, Toh CK, Ng QS, Chowbay B and Lim WT: Phase I study of oral
vinorelbine in combination with erlotinib in advanced non-small
cell lung cancer (NSCLC) using two different schedules. PLoS One.
11:e01543162016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gusella M, Pasini F, Caruso D, Barile C,
Modena Y, Fraccon AP, Bertolaso L, Menon D, Crepaldi G, Bononi A,
et al: Clinical outcomes of oral metronomic vinorelbine in advanced
non-small cell lung cancer: Correlations with pharmacokinetics and
MDR1 polymorphisms. Cancer Chemother Pharmacol. 83:493–500. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Orlandi P, Di Desidero T, Salvia G,
Muscatello B, Francia G and Bocci G: Metronomic vinorelbine is
directly active on non small cell lung cancer cells and sensitizes
the EGFR(L858R/T790M) cells to reversible EGFR tyrosine kinase
inhibitors. Biochem Pharmacol. 152:327–337. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qin RS, Zhang ZH, Zhu NP, Chen F, Guo Q,
Hu HW, Fu SZ, Liu SS, Chen Y, Fan J and Han YW: Enhanced antitumor
and anti-angiogenic effects of metronomic Vinorelbine combined with
Endostar on Lewis lung carcinoma. BMC Cancer. 18:9672018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang R, Qin S, Chen Y, Li Y, Chen C, Wang
Z, Zheng R and Wu Q: Enhanced anti-tumor and anti-angiogenic
effects of metronomic cyclophosphamide combined with Endostar in a
xenograft model of human lung cancer. Oncol Rep. 28:439–445. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tan EH, Tan DS, Li WY, Haaland B, Ang MK,
Chau NM, Toh CK, Tan IB, Koh TS, Thng CH, et al: Metronomic
vinorelbine (oral) in combination with sorafenib in advanced
non-small cell lung cancer. Lung Cancer. 88:289–296. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Correale P, Remondo C, Carbone SF, Ricci
V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L,
Gotti G, et al: Dose/dense metronomic chemotherapy with fractioned
cisplatin and oral daily etoposide enhances the anti-angiogenic
effects of bevacizumab and has strong antitumor activity in
advanced non-small-cell-lung cancer patients. Cancer Biol Ther.
9:685–693. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Correale P, Botta C, Basile A, Pagliuchi
M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R,
Misso G, et al: Phase II trial of bevacizumab and dose/dense
chemotherapy with cisplatin and metronomic daily oral etoposide in
advanced non-small-cell-lung cancer patients. Cancer Biol Ther.
12:112–118. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Marquette CL, Grant SC, DeShazo M, Reddy
V, Cantor A, MileyMary Jerome D and Robert F: Phase II study of
metronomic chemotherapy (MC) with bevacizumab (B) in patients (Pts)
with advanced (Adv) nonsquamous non-small cell lung cancer
(NS-NSCLC). J Clin Oncol. 31 (15 Suppl):S80572013. View Article : Google Scholar
|
|
49
|
Revannasiddaiah S and Susheela SP:
Chemically enhanced radiotherapy: Visions for the future. Ann
Transl Med. 4:522016.PubMed/NCBI
|
|
50
|
Revannasiddaiah S, Joshi SC, Pandey KC,
Rastogi M, Sharma M and Gupta M: The results with the addition of
metronomic cyclophosphamide to palliative radiotherapy for the
treatment of non-small cell lung carcinoma. Ann Transl Med.
3:3052015.PubMed/NCBI
|
|
51
|
Pastina P, Nardone V, Botta C, Croci S,
Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, et al:
Radiotherapy prolongs the survival of advanced non-small-cell lung
cancer patients undergone to an immune-modulating treatment with
dose-fractioned cisplatin and metronomic etoposide and bevacizumab
(mPEBev). Oncotarget. 8:75904–75913. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Moserle L, Amadori A and Indraccolo S: The
angiogenic Switch: Implications in the regulation of tumor
dormancy. Curr Mol Med. 9:935–941. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Correale P, Remondo C, Carbone SF, Ricci
V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L,
Gotti G, et al: Dose/dense metronomic chemotherapy with fractioned
cisplatin and oral daily etoposide enhances the anti-angiogenic
effects of bevacizumab and has strong antitumor activity in
advanced non-small-cell-lung cancer patients. Cancer Biol Ther.
9:685–693. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Shaikh AJ and Masood N: Acute
lymphoblastic leukemia subsequent to temozolomide use in a
26-year-old man: A case report. J Med Case Rep. 4:2742010.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Le Deley MC, Leblanc T, Shamsaldin A,
Raquin MA, Lacour B, Sommelet D, Chompret A, Cayuela JM, Bayle C,
Bernheim A, et al: Risk of secondary leukemia after a solid tumor
in childhood according to the dose of epipodophyllotoxins and
anthracyclines: A case-control study by the Societe Francaise
d'Oncologie Pediatrique. J Clin Oncol. 21:1074–1081. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Vergnenegre A, Monnet I, Bizieux A,
Bernardi M, Chiapa AM, Léna H, Chouaïd C and Robinet G: Open-label
Phase II trial to evaluate safety and efficacy of second-line
metronomic oral vinorelbine-atezolizumab combination for stage-IV
non-small-cell lung cancer-VinMetAtezo trial, (GFPC‡
04–2017). Future Oncol. 16:5–10. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Platania M, Pasini F, Porcu L, Boeri M,
Verderame F, Modena Y, Del Conte A, Nichetti F, Garassino MC,
Martinetti A, et al: Oral maintenance metronomic vinorelbine versus
best supportive care in advanced non-small-cell lung cancer after
platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized,
controlled, phase II trial. Lung Cancer. 132:17–23. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Munzone E and Colleoni M: Clinical
overview of metronomic chemotherapy in breast cancer. Nat Rev Clin
Oncol. 12:631–644. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
de Castro G, Puglisi F, de Azambuja E, El
Saghir NS and Awada A: Angiogenesis and cancer: A cross-talk
between basic science and clinical trials (the ‘do ut des’
paradigm). Crit Rev Oncol Hemat. 59:40–50. 2006. View Article : Google Scholar
|
|
61
|
Kerbel RS: A decade of experience in
developing preclinical models of advanced- or Early-stage
spontaneous metastasis to study antiangiogenic drugs, metronomic
chemotherapy, and the tumor microenvironment. Cancer J. 21:274–283.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Maiti R: Metronomic chemotherapy. J
Pharmacol Pharmacother. 5:186–192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bocci G, Nicolaou KC and Kerbel RS:
Protracted low-dose effects on human endothelial cell proliferation
and survival in vitro reveal a selective antiangiogenic window for
various chemotherapeutic drugs. Cancer Res. 62:6938–6943.
2002.PubMed/NCBI
|
|
64
|
Grant DS, Williams TL, Zahaczewsky M and
Dicker AP: Comparison of antiangiogenic activities using paclitaxel
(taxol) and docetaxel (taxotere). Int J Cancer. 104:121–129. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bertolini F, Paul S, Mancuso P,
Monestiroli S, Gobbi A, Shaked Y and Kerbel RS: Maximum tolerable
dose and low-dose metronomic chemotherapy have opposite effects on
the mobilization and viability of circulating endothelial
progenitor cells. Cancer Res. 63:4342–4346. 2003.PubMed/NCBI
|
|
66
|
Mpekris F, Baish JW, Stylianopoulos T and
Jain RK: Role of vascular normalization in benefit from metronomic
chemotherapy. Proc Natl Acad Sci USA. 114:1994–1999. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sarmiento R and Gasparini G:
Antiangiogenic metronomic chemotherapy. Onkologie. 31:161–162.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Laquente B, Vinals F and Germa JR:
Metronomic chemotherapy: An antiangiogenic scheduling. Clin Transl
Oncol. 9:93–98. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Pasquier E, Kavallaris M and Andre N:
Metronomic chemotherapy: New rationale for new directions. Nat Rev
Clin Oncol. 7:455–465. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Andre N, Carre M and Pasquier E:
Metronomics: Towards personalized chemotherapy? Nat Rev Clin Oncol.
11:413–431. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ghiringhelli F, Menard C, Puig PE, Ladoire
S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L and Chauffert
B: Metronomic cyclophosphamide regimen selectively depletes
CD4+CD25+ regulatory T cells and restores T and NK effector
functions in end stage cancer patients. Cancer Immunol Immunother.
56:641–648. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Shaked Y, Pham E, Hariharan S, Magidey K,
Beyar-Katz O, Xu P, Man S, Wu FT, Miller V, Andrews D and Kerbel
RS: Evidence Implicating immunological host effects in the efficacy
of metronomic low-dose chemotherapy. Cancer Res. 76:5983–5993.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kosmaczewska A, Ciszak L, Potoczek S and
Frydecka I: The significance of Treg cells in defective tumor
immunity. Arch Immunol Ther Exp (Warsz). 56:181–191. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hao YB, Yi SY, Ruan J, Zhao L and Nan KJ:
New insights into metronomic chemotherapy-induced immunoregulation.
Cancer Lett. 354:220–226. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Banissi C, Ghiringhelli F, Chen L and
Carpentier AF: Treg depletion with a low-dose metronomic
temozolomide regimen in a rat glioma model. Cancer Immunol
Immunother. 58:1627–1634. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Ghiringhelli F, Ménard C, Martin F and
Zitvogel L: The role of regulatory T cells in the control of
natural killer cells: Relevance during tumor progression. Immunol
Rev. 214:229–238. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kodumudi KN, Woan K, Gilvary DL, Sahakian
E, Wei S and Djeu JY: A novel chemoimmunomodulating property of
docetaxel: Suppression of myeloid-derived suppressor cells in tumor
bearers. Clin Cancer Res. 16:4583–4594. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Sevko A, Michels T, Vrohlings M, Umansky
L, Beckhove P, Kato M, Shurin GV, Shurin MR and Umansky V:
Antitumor effect of paclitaxel is mediated by inhibition of
myeloid-derived suppressor cells and chronic inflammation in the
spontaneous melanoma model. J Immunol. 190:2464–2471. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Vincent J, Mignot G, Chalmin F, Ladoire S,
Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and
Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated
myeloid-derived suppressor cells resulting in enhanced T
cell-dependent antitumor immunity. Cancer Res. 70:3052–3061. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Bracci L, Schiavoni G, Sistigu A and
Belardelli F: Immune-based mechanisms of cytotoxic chemotherapy:
Implications for the design of novel and rationale-based combined
treatments against cancer. Cell Death Differ. 21:15–25. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kareva I, Waxman DJ and Lakka Klement G:
Metronomic chemotherapy: An attractive alternative to maximum
tolerated dose therapy that can activate anti-tumor immunity and
minimize therapeutic resistance. Cancer Lett. 358:100–106. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Martin-Padura I, Marighetti P, Agliano A,
Colombo F, Larzabal L, Redrado M, Bleau AM, Prior C, Bertolini F
and Calvo A: Residual dormant cancer stem-cell foci are responsible
for tumor relapse after antiangiogenic metronomic therapy in
hepatocellular carcinoma xenografts. Lab Invest. 92:952–966. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Folkins C, Man S, Xu P, Shaked Y, Hicklin
DJ and Kerbel RS: Anticancer therapies combining antiangiogenic and
tumor cell cytotoxic effects reduce the tumor stem-like cell
fraction in glioma xenograft tumors. Cancer Res. 67:3560–3564.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Vives M, Ginesta MM, Gracova K, Graupera
M, Casanovas O, Capellà G, Serrano T, Laquente B and Viñals F:
Metronomic chemotherapy following the maximum tolerated dose is an
effective anti-tumour therapy affecting angiogenesis, tumour
dissemination and cancer stem cells. Int J Cancer. 133:2464–2472.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Yan H, Chen X, Zhang QP, Qin J, Li H, Liu
C, Calhoun-Davis T, Coletta LD, Klostergaard J, Fokt I, et al:
Drug-tolerant cancer cells show reduced tumor-initiating capacity:
Depletion of CD44(+) cells and evidence for epigenetic mechanisms.
PLoS One. 6:e243972011. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Aguirre-Ghiso JA: Models, mechanisms and
clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Udagawa T: Tumor dormancy of primary and
secondary cancers. Apmis. 116:615–628. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Natale G and Bocci G: Does metronomic
chemotherapy induce tumor angiogenic dormancy? A review of
available preclinical and clinical data. Cancer Lett. 432:28–37.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Schirrmacher V: T-cell immunity in the
induction and maintenance of a tumour dormant state. Semin Cancer
Biol. 11:285–295. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Weir G, Hrytsenko O, Stanford M, Karkada
M, Berinstein N and Mansour M: Abstract 2508: Multi-modal treatment
with peptide vaccine, metronomic cyclophosphamide and anti-PD1
monoclonal antibody provides effective control of tumors in
multiple models. Cancer Res. 752015.doi:
10.1158/1538-7445.AM2015-2508.
|
|
91
|
Rajasekaran T, Ng QS, Tan DS, Lim WT, Ang
MK, Toh CK, Chowbay B, Kanesvaran R and Tan EH: Metronomic
chemotherapy: A relook at its basis and rationale. Cancer Lett.
388:328–333. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Eichhorn ME, Ischenko I, Luedemann S,
Strieth S, Papyan A, Werner A, Bohnenkamp H, Guenzi E, Preissler G,
Michaelis U, et al: Vascular targeting by EndoTAG-1 enhances
therapeutic efficacy of conventional chemotherapy in lung and
pancreatic cancer. Int J Cancer. 126:1235–1245. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Panigrahy D, Kaipainen A, Butterfield CE,
Chaponis DM, Laforme AM, Folkman J and Kieran MW: Inhibition of
tumor angiogenesis by oral etoposide. Exp Ther Med. 1:739–746.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Jones BS, Jerome MS, Miley D, Jackson BE,
DeShazo MR, Reddy VV, Singh KP, Brown OC and Robert F: Pilot phase
II study of metronomic chemotherapy in combination with bevacizumab
in patients with advanced non-squamous non-small cell lung cancer.
Lung Cancer. 106:125–130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Giorgio CG, Giuffrida D, Pappalardo A,
Russo A, Santini D, Salice P, Blanco G, Castorina S, Failla G and
Bordonaro R: Oral temozolomide in heavily pre-treated brain
metastases from non-small cell lung cancer: Phase II study. Lung
Cancer. 50:247–254. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Banna GL, Camerini A, Bronte G, Anile G,
Addeo A, Rundo F, Zanghì G, Lal R and Libra M: Oral metronomic
vinorelbine in advanced non-small cell lung cancer patients unfit
for chemotherapy. Anticancer Res. 38:3689–3697. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Bilir C, Durak S, Kizilkaya B,
Hacibekiroglu I, Nayir E and Engin H: Efficacy of metronomic
vinorelbine in elderly patients with advanced non-small-cell lung
cancer and poor performance status. Curr Oncol. 24:e199–e204. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Mencoboni M, Filiberti RA, Taveggia P, Del
Corso L, Del Conte A, Covesnon MG, Puccetti C, Donati S, Auriati L,
Amoroso D and Camerini A: Safety of first-line chemotherapy with
metronomic single-agent oral vinorelbine in elderly patients with
NSCLC. Anticancer Res. 37:3189–3194. 2017.PubMed/NCBI
|
